ストックスクリーナーアプリを入手
59.51
0.52%
-0.31
アフターアワーズ：
59.51
前日終値:
$59.82
開ける：
$60
24時間の取引高:
2.62M
Relative Volume:
1.07
時価総額：
$14.75B
収益：
$2.38B
当期純損益:
$833.42M
株価収益率:
19.72
EPS:
3.0172
ネットキャッシュフロー:
$917.69M
1週間 パフォーマンス:
+2.02%
1か月 パフォーマンス:
+6.04%
6か月 パフォーマンス:
+32.36%
1年 パフォーマンス:
+54.81%
1日の値動き範囲:
$58.59
$60.00
1週間の範囲:
$57.88
$61.66
52週間の値動き範囲:
$33.76
$61.66
Exelixis Inc Stock (EXEL) Company Profile
Compare EXEL vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
59.51 | 14.75B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2026-08-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-06-25 | 再開されました | Truist | Hold |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-11-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 開始されました | Goldman | Buy |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView
Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa
Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill
Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com
RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance
EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus
Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance
Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance
Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance
Is Exelixis Stock Engineered To Make You Money? - Trefis
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents - The National Law Review
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents - The National Law Review
Exelixis delays cancer-drug review: what it means for Exelixis stock - AD HOC NEWS
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup - ChartMill
Exelixis, Inc. - Simply Wall Street
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content - finance.biggo.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Shares Rising on CABOMETYX Revenue - Yahoo Finance
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com Nigeria
Exelixis stock hits all-time high at 59.73 USD - Investing.com
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com South Africa
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Exelixis, Inc. (EXEL) Stock forecasts - au.finance.yahoo.com
Cash flow from operating activities of Exelixis, Inc. – HAN:EX9 - TradingView
Return on equity % of Exelixis, Inc. – HAN:EX9 - TradingView
Exelixis (NasdaqGS:EXEL) Stock Forecast & Analyst Predictions - Simply Wall Street
Exelixis, Inc. (EXEL) Stock forecasts - sg.finance.yahoo.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - TradingView
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - easternprogress.com
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Exelixis (EXEL) Slips 0.22% to $58.36, Key Support and Resistance in FocusRisk Reward Setups - careplusvn.com
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B - Yahoo Finance
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Inc (EX9.MU) Stock Price, News, Quote & History - Yahoo Finance
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Potential Amidst a Competitive Biotech Landscape - DirectorsTalk Interviews
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
Exelixis Inc (EXEL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MARY BECKERLE | Director |
Aug 10 '26 |
Proposed Sale |
53.66 |
9,812 |
526,496 |
0 |
| JACK L WYSZOMIERSKI | Director |
Jun 01 '26 |
Proposed Sale |
50.55 |
3,925 |
198,409 |
0 |
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Sale |
50.14 |
9,812 |
491,974 |
16,079 |
| WYSZOMIERSKI JACK L | Director |
Jun 01 '26 |
Sale |
50.55 |
3,925 |
198,409 |
284,384 |
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Proposed Sale |
50.87 |
9,812 |
499,136 |
0 |
| Aftab Dana | EVP, Research and Development |
May 26 '26 |
Sale |
50.35 |
43,451 |
2,187,758 |
594,741 |
| DANA T AFTAB | Officer |
May 26 '26 |
Proposed Sale |
50.35 |
43,451 |
2,187,758 |
0 |
| PATRICK JOSEPH HALEY | Officer |
May 20 '26 |
Proposed Sale |
49.81 |
32,110 |
1,599,444 |
0 |
| Haley Patrick J. | EVP, Commercial |
May 20 '26 |
Sale |
49.81 |
32,110 |
1,599,399 |
357,638 |
| BRENDA JOY HEFTI | Officer |
May 18 '26 |
Proposed Sale |
50.21 |
6,625 |
332,641 |
0 |
1.67%
大文字化:
|
ボリューム (24 時間):